Defeating stem cell tourism

The Orphan Drug Act and the Development of Stem Cell-Based Products for Rare Diseases

(2010) Scott N. Freeman et al.   Cell Stem Cell

Patients Beware: Commercialized Stem Cell Treatments on the Web

(2010) Patrick L. Taylor et al.   Cell Stem Cell

The FDA's critical path initiative: A brief introduction

(2010) Stephen Joel Coons   CLINICAL THERAPEUTICS

Angiomyeloproliferative Lesions Following Autologous Stem Cell Therapy

(2010) D. Thirabanjasak et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The Translation Cycle: round and round in cycles is the only way forward for regenerative medicine

(2010) Chris Mason et al.   Regenerative Medicine

Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010

(2010) Chris Mason et al.   Regenerative Medicine

Going Off-label Without Venturing Off-Course

(2009) Emily A. Largent   ARCHIVES OF INTERNAL MEDICINE

Interview: Progress on the FDA’s Critical Path Initiative

(2009) Janet Woodcock   Biomarkers in Medicine

Regen: the industry responsible for cell-based therapies

(2009) Chris Mason et al.   Regenerative Medicine

Product Regulation and the Clinical Translation of Stem Cell Research

(2009) Barbara von Tigerstrom   Stem Cell Reviews and Reports

Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease

(2009) Olle Lindvall et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient

(2009) Ninette Amariglio et al.   PLOS MEDICINE

New ISSCR Guidelines Underscore Major Principles for Responsible Translational Stem Cell Research

(2008) Insoo Hyun et al.   Cell Stem Cell

Off-label or off-limits?

(2008) Mark Ratner et al.   NATURE BIOTECHNOLOGY